Skip to main content
HealthcareEvidence

Back within reach of the 2021 peak, but funding different things

Biotech venture funding peaked near $42bn in 2021, fell through the 2022–23 funding winter as rate rises closed the IPO window, and recovered to about $38bn in 2025, a 28% gain on 2024.

Biopharma specifically raised $23.3bn in 2023 and $26bn in 2024, with a higher share going to clinically de-risked assets rather than pre-clinical platform bets.

Biotech Venture Funding

Data date
2025
Source class
Reputable secondary
Data points
5
Sources
3
Value basis
5 actual

This page can answer

Two series: global biotech venture funding, and biopharma-specific venture funding.

It cannot answer

  • Stage or therapeutic-area breakdowns.
  • Deal counts or median round sizes.
  • Returns or exit outcomes.
Jump to chaptersSource ledger
Evidence chapters

Chapter 01 · Question answered

Venture capital invested in biotech.

Global biotech venture funding

Global biotech VC

Global biotech VC

Venture capital invested in biotech, $ billions.

View data & sources →

Global biotech VC

Rendering the interactive chart…

Expand data table
Download CSV

Global biotech venture funding: full data table

SOURCEMcKinsey: Next-generation platform technologies are driving the biotech VC surge
VALUE BASISActual
LAST VERIFIEDSep 10, 2026
How this is calculated

Chapter 02 · Question answered

Venture capital raised by biopharma companies.

Biopharma-specific venture funding

Biopharma VC

Biopharma VC

Venture capital raised by biopharma companies, $ billions.

View data & sources →

Biopharma VC

Rendering the interactive chart…

Expand data table
Download CSV
Biopharma-specific venture funding: data table
PeriodSeriesValueValue basisSource
2023$bn raised23.3ActualBioPharma Dive: Biotech venture capital funding tracker
2024$bn raised26ActualBioPharma Dive: Biotech venture capital funding tracker

Biopharma-specific venture funding: full data table

SOURCEBioPharma Dive: Biotech venture capital funding tracker
VALUE BASISActual
LAST VERIFIEDSep 10, 2026
How this is calculated
All data for this index

Data table

Download CSV

Method

How this evidence was built

What it measures

Two series with deliberately different scopes: "global biotech" is the broad sector total, "biopharma" is the narrower drug-developer subset. They are not alternative estimates of the same quantity and should not be compared point-to-point.

Key context

  • Venture funding totals vary materially between data providers depending on whether crossover rounds, corporate venture and non-dilutive grants are counted.
  • Each series here is kept to a single provider so the trend within a series is consistent.

Key numbers

  • Biotech VC peaked near $42bn in 2021 (mckinsey-biotech-vc).
  • Recovery to ~$38bn in 2025, a 28% gain on $29.7bn in 2024 (mckinsey-biotech-vc).
  • Biopharma raised $23.3bn (2023) and $26bn (2024) (biopharmadive-tracker).

Caveats

Caveat: 2020, 2022 and 2023 global totals are described qualitatively in the cited sources as a "funding winter" but no figure is published, so those years are omitted rather than estimated from the narrative.

Do not use this to

  • Stage or therapeutic-area breakdowns.
  • Deal counts or median round sizes.
  • Returns or exit outcomes.

Scope

2025

Sources

Last verified 10 Sept 2026

Methods that use this evidence

Use one of these copy-paste methods when you want an AI to work from this evidence.

How relevant was this information?